In vivo activity of LCB 01-0699, a prodrug of LCB 01-0648, against staphylococcus aureus

Sang Hun Oh; Hee Soo Park; Jun Hyung Lee; Sung Yun Baek; Sang Eun Chae; Kyuman Oh; Young Lag Cho; Jin Hwan Kwak

doi:10.3390/molecules22122096

In vivo activity of LCB 01-0699, a prodrug of LCB 01-0648, against staphylococcus aureus

Sang Hun Oh, Hee Soo Park, Jun Hyung Lee, Sung Yun Baek, Sang Eun Chae, Kyuman Oh, Young Lag Cho, Jin Hwan Kwak

School of Food Science & Biotechnology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

LCB01-0648 is a novel oxazolidinone compound that shows potent antibacterial activities against most Gram-positive cocci, including the multi-drug resistant Staphylococcus aureus. In this study, in vivo activity of LCB01-0699, a LCB01-0648 prodrug, against S. aureus was evaluated in comparison with that of Linezolid. The results of the systemic infection study demonstrated that LCB01-0699 was more potent than Linezolid against methicillin-susceptible and-resistant S. aureus strains. The in vivo efficacy of LCB01-0699 against methicillin-susceptible and-resistant S. aureus strains in a skin infection model showed more potent activity than Linezolid. LCB01-0699 shows potent in vivo activity against methicillin-susceptible and-resistant S. aureus strains, suggesting that LCB01-0699 would be a novel candidate for the treatment of these infectious diseases caused by S. aureus.

Original language	English
Article number	2096
Journal	Molecules
Volume	22
Issue number	12
DOIs	https://doi.org/10.3390/molecules22122096
State	Published - Dec 2017

Keywords

In vivo activity
LCB01-0648
LCB01-0699
Oxazolidinone
Skin infection

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/molecules22122096

Cite this

@article{4deea4743c554b33ae561a40efe1876c,

title = "In vivo activity of LCB 01-0699, a prodrug of LCB 01-0648, against staphylococcus aureus",

abstract = "LCB01-0648 is a novel oxazolidinone compound that shows potent antibacterial activities against most Gram-positive cocci, including the multi-drug resistant Staphylococcus aureus. In this study, in vivo activity of LCB01-0699, a LCB01-0648 prodrug, against S. aureus was evaluated in comparison with that of Linezolid. The results of the systemic infection study demonstrated that LCB01-0699 was more potent than Linezolid against methicillin-susceptible and-resistant S. aureus strains. The in vivo efficacy of LCB01-0699 against methicillin-susceptible and-resistant S. aureus strains in a skin infection model showed more potent activity than Linezolid. LCB01-0699 shows potent in vivo activity against methicillin-susceptible and-resistant S. aureus strains, suggesting that LCB01-0699 would be a novel candidate for the treatment of these infectious diseases caused by S. aureus.",

keywords = "In vivo activity, LCB01-0648, LCB01-0699, Oxazolidinone, Skin infection",

author = "Oh, {Sang Hun} and Park, {Hee Soo} and Lee, {Jun Hyung} and Baek, {Sung Yun} and Chae, {Sang Eun} and Kyuman Oh and Cho, {Young Lag} and Kwak, {Jin Hwan}",

note = "Publisher Copyright: {\textcopyright} 2017 by the authors.",

year = "2017",

month = dec,

doi = "10.3390/molecules22122096",

language = "English",

volume = "22",

journal = "Molecules",

issn = "1420-3049",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "12",

}

TY - JOUR

T1 - In vivo activity of LCB 01-0699, a prodrug of LCB 01-0648, against staphylococcus aureus

AU - Oh, Sang Hun

AU - Park, Hee Soo

AU - Lee, Jun Hyung

AU - Baek, Sung Yun

AU - Chae, Sang Eun

AU - Oh, Kyuman

AU - Cho, Young Lag

AU - Kwak, Jin Hwan

PY - 2017/12

Y1 - 2017/12

N2 - LCB01-0648 is a novel oxazolidinone compound that shows potent antibacterial activities against most Gram-positive cocci, including the multi-drug resistant Staphylococcus aureus. In this study, in vivo activity of LCB01-0699, a LCB01-0648 prodrug, against S. aureus was evaluated in comparison with that of Linezolid. The results of the systemic infection study demonstrated that LCB01-0699 was more potent than Linezolid against methicillin-susceptible and-resistant S. aureus strains. The in vivo efficacy of LCB01-0699 against methicillin-susceptible and-resistant S. aureus strains in a skin infection model showed more potent activity than Linezolid. LCB01-0699 shows potent in vivo activity against methicillin-susceptible and-resistant S. aureus strains, suggesting that LCB01-0699 would be a novel candidate for the treatment of these infectious diseases caused by S. aureus.

AB - LCB01-0648 is a novel oxazolidinone compound that shows potent antibacterial activities against most Gram-positive cocci, including the multi-drug resistant Staphylococcus aureus. In this study, in vivo activity of LCB01-0699, a LCB01-0648 prodrug, against S. aureus was evaluated in comparison with that of Linezolid. The results of the systemic infection study demonstrated that LCB01-0699 was more potent than Linezolid against methicillin-susceptible and-resistant S. aureus strains. The in vivo efficacy of LCB01-0699 against methicillin-susceptible and-resistant S. aureus strains in a skin infection model showed more potent activity than Linezolid. LCB01-0699 shows potent in vivo activity against methicillin-susceptible and-resistant S. aureus strains, suggesting that LCB01-0699 would be a novel candidate for the treatment of these infectious diseases caused by S. aureus.

KW - In vivo activity

KW - LCB01-0648

KW - LCB01-0699

KW - Oxazolidinone

KW - Skin infection

UR - http://www.scopus.com/inward/record.url?scp=85040342534&partnerID=8YFLogxK

U2 - 10.3390/molecules22122096

DO - 10.3390/molecules22122096

M3 - Article

C2 - 29186032

AN - SCOPUS:85040342534

SN - 1420-3049

VL - 22

JO - Molecules

JF - Molecules

IS - 12

M1 - 2096

ER -

In vivo activity of LCB 01-0699, a prodrug of LCB 01-0648, against staphylococcus aureus

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this